Crossmatching by complement-dependent lymphocytotoxicity.
The presence of preformed donor-specific HLA antibodies detected by Complement-dependent cyto-toxicity (CDC) crossmatch assay is associated with a high incidence of hyperacute or accelerated rejection and remains one of the gold standard tests pre-transplant. The standard CDC crossmatch detects IgG1, IgG3, and IgM antibody, i.e. complement fixing, bound to the native viable cell surface of lymphocytes. The crossmatch can be enhanced with the addition of anti-human-globulin to detect non-complement fixing antibodies (IgG2 and IgG4), and sensitivity can be improved with prolonged incubation times.